相关实验视频

Updated: Jul 19, 2025

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

免疫疗法和跨动脉放射栓塞组合治疗高级肝细胞癌的治疗方法

Yee Hui Yeo¹, Jeff Liang², Marie Lauzon³

¹Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.

The American journal of gastroenterology

|August 10, 2023

概括

与免疫疗法相结合的跨动脉放射栓塞 (TARE) 与免疫疗法显著改善了晚期肝细胞癌 (HCC) 患者的生存率,而不是仅仅免疫疗法. 这一发现支持TARE和免疫疗法联合治疗的更大规模临床试验.

科学领域:

肝胆瘤学肝胆瘤学
干预性放射学干预性放射学
免疫疗法研究免疫疗法研究

背景情况:

临床前和早期阶段的试验表明,联合免疫疗法和跨动脉放射栓塞 (TARE) 的疗效.
之前的研究受限于小样本大小,需要进行更大的调查.

研究的目的:

为了比较联合TARE和免疫治疗与单独免疫治疗在晚期肝细胞癌 (HCC) 的疗效.

主要方法:

利用国家癌症数据库 (2017-2019) 对接受一线治疗的高级HCC患者.
在生存分析中使用多变量逻辑回归,卡普兰-梅尔和考克斯回归.
进行的倾向性得分匹配和治疗权重的逆概率,用于敏感性分析.

主要成果:

分析了1,664名患者:142人接受了TARE/免疫疗法的联合治疗,1,522人仅接受了免疫疗法.
组合治疗组 (19.8个月) 与单独免疫治疗组 (9.5个月) 的平均整体存活时间显著更高.
联合治疗独立与降低死亡率相关 (aHR 0.50;P < 0.001).

结论:

结合TARE和免疫疗法,在晚期HCC患者中改善了生存率.
研究结果强调需要进行大型临床试验,以进一步评估这种组合疗法.

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...